228118-56-7

Basic information

• Product Name: 2-(4-chlorophenyl)-6,7-dimethoxyquinazolin-4(3H)-one
• Synonyms: 2-(4-chlorophenyl)-6,7-dimethoxyquinazolin-4(3H)-one
• CAS NO: 228118-56-7
• Molecular Weight: 316.744
• Mol File: 228118-56-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-(4-chlorophenyl)-6,7-dimethoxyquinazolin-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-chlorophenyl)-6,7-dimethoxyquinazolin-4(3H)-one(228118-56-7)
• EPA Substance Registry System: 2-(4-chlorophenyl)-6,7-dimethoxyquinazolin-4(3H)-one(228118-56-7)

Safety Data

• Hazardous Substances Data: 228118-56-7(Hazardous Substances Data)

Upstream product

• 6212-33-5 2-(4-Chlorophenyl)glycine 
• 102714-71-6 4,5-dimethoxy-2-nitrobenzonitrile 
• 4959-60-8 4,5-dimethoxy-2-nitrobenzamide 
• 4998-07-6 4,5-dimethoxy-2-nitro-benzoic acid 
• 5004-88-6 4,5-dimethoxyanthranilamide 
• 228118-55-6 2-((4-chlorophenyl)carbonylamino)-4,5-dimethoxybenzamide 
• 74-11-3 para-chlorobenzoic acid 
• 122-01-0 4-chloro-benzoyl chloride 
• 26961-27-3 2-amino-4,5-dimethoxybenzonitrile 
• 857534-65-7 2-(4-chloro-benzoylamino)-4,5-dimethoxy-benzonitrile 

Downstream Products

• 228118-57-8 4-chloro-2-(4-chlorophenyl)-6,7-dimethoxyquinazoline 

Relevant articles and documents

6,7-dimethoxyquinazolines as potential cytotoxic agents: Synthesis and in vitro activity

It has been reported that 6,7-dimethoxyquinazoline derivatives have cytotoxic potential independent of their a1-adrenoceptor blocking potential. Bioisosteres of 2-arylquinazolines are considered to have anti-tumor properties. In the present study, we have synthesized the 2-aryl and 2-arylmethyl derivatives of quinazolin-4(3H)-one while retaining the 6,7-dimethoxy substituents. Derivatives with n-butyl group attached to position-3 of quinazolinone nucleus were synthesized with the aim of increasing their lipophilicity. The potential of these synthesized compounds was evaluated against NCI (National Cancer Institute) 60 cell panel using the NCI disease oriented antitumor screen protocol. Based on the results of this screening we generalized that compounds having aryl groups directly attached to the quinazoline ring are less active than those which have one atom linker in between the two ring systems. Substitution of a lipophilic group like nbutyl decreases cytotoxic activity among the compounds and 4-aminoquinazolines showed better activity than 4-quinazolinones. Lipophilic groups in the aromatic ring yielded more active compounds as cytotoxic agents. Among the selected compounds, 4h and 13b were found to be potential lead compounds which could be further optimized as potential anti-neoplastic agents.

SUBSTITUTED 4-(SELENOPHEN-2(OR-3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF

Selenophene compounds of formula (I) are described herein. In the compounds of Formula (I), ring A is a 6-membered aromatic fused ring, optionally containing one, two or three nitrogen atoms; a 5-membered heteroaromatic fused ring; or a mono- or bicyclic